EVERSPIN TECHNOLOGIES INC (MRAM)

US30041T1043 - Common Stock

6.26  +0.13 (+2.12%)

After market: 6.26 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to MRAM. MRAM was compared to 109 industry peers in the Semiconductors & Semiconductor Equipment industry. MRAM has a great financial health rating, but its profitability evaluates not so good. MRAM has a correct valuation and a medium growth rate.



3

1. Profitability

1.1 Basic Checks

In the past year MRAM was profitable.
In the past year MRAM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MRAM reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MRAM reported negative operating cash flow in multiple years.

1.2 Ratios

MRAM has a Return On Assets of 2.11%. This is comparable to the rest of the industry: MRAM outperforms 51.85% of its industry peers.
The Return On Equity of MRAM (2.59%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA 2.11%
ROE 2.59%
ROIC N/A
ROA(3y)11.85%
ROA(5y)-6.42%
ROE(3y)16.19%
ROE(5y)-15.93%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin of MRAM (2.85%) is comparable to the rest of the industry.
The Gross Margin of MRAM (53.90%) is better than 73.15% of its industry peers.
In the last couple of years the Gross Margin of MRAM has grown nicely.
Industry RankSector Rank
OM N/A
PM (TTM) 2.85%
GM 53.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.71%
GM growth 5Y2.65%

8

2. Health

2.1 Basic Checks

MRAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRAM has been increased compared to 1 year ago.
The number of shares outstanding for MRAM has been increased compared to 5 years ago.
There is no outstanding debt for MRAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 4.99 indicates that MRAM is not in any danger for bankruptcy at the moment.
MRAM has a Altman-Z score (4.99) which is comparable to the rest of the industry.
There is no outstanding debt for MRAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.99
ROIC/WACCN/A
WACC14.47%

2.3 Liquidity

A Current Ratio of 6.74 indicates that MRAM has no problem at all paying its short term obligations.
MRAM's Current ratio of 6.74 is amongst the best of the industry. MRAM outperforms 89.81% of its industry peers.
MRAM has a Quick Ratio of 5.85. This indicates that MRAM is financially healthy and has no problem in meeting its short term obligations.
MRAM has a better Quick ratio (5.85) than 90.74% of its industry peers.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 5.85

4

3. Growth

3.1 Past

MRAM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.53%.
The Revenue for MRAM has decreased by -14.17% in the past year. This is quite bad
Measured over the past years, MRAM shows a small growth in Revenue. The Revenue has been growing by 5.23% on average per year.
EPS 1Y (TTM)-25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-14.17%
Revenue growth 3Y14.91%
Revenue growth 5Y5.23%
Sales Q2Q%-26.56%

3.2 Future

Based on estimates for the next years, MRAM will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.46% on average per year.
MRAM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.72% yearly.
EPS Next Y-47.11%
EPS Next 2Y-22.25%
EPS Next 3Y18.46%
EPS Next 5YN/A
Revenue Next Year-20.81%
Revenue Next 2Y-7.89%
Revenue Next 3Y13.72%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 17.89, which indicates a rather expensive current valuation of MRAM.
Compared to the rest of the industry, the Price/Earnings ratio of MRAM indicates a rather cheap valuation: MRAM is cheaper than 81.48% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.28, MRAM is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 19.18, the valuation of MRAM can be described as rather expensive.
77.78% of the companies in the same industry are more expensive than MRAM, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.53, MRAM is valued at the same level.
Industry RankSector Rank
PE 17.89
Fwd PE 19.18

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, MRAM is valued a bit cheaper than the industry average as 72.22% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 37.39
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MRAM's earnings are expected to grow with 18.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.25%
EPS Next 3Y18.46%

0

5. Dividend

5.1 Amount

MRAM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

EVERSPIN TECHNOLOGIES INC

NASDAQ:MRAM (1/14/2025, 8:00:01 PM)

After market: 6.26 0 (0%)

6.26

+0.13 (+2.12%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)N/A N/A
Inst Owners61.01%
Inst Owner Change0%
Ins Owners3.86%
Ins Owner Change-2.2%
Market Cap137.53M
Analysts82.5
Price Target9.18 (46.65%)
Short Float %2.74%
Short Ratio4.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)908.82%
Min EPS beat(2)50.98%
Max EPS beat(2)1766.67%
EPS beat(4)4
Avg EPS beat(4)465.38%
Min EPS beat(4)14.38%
Max EPS beat(4)1766.67%
EPS beat(8)8
Avg EPS beat(8)271.82%
EPS beat(12)12
Avg EPS beat(12)722.37%
EPS beat(16)16
Avg EPS beat(16)628.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.65%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-1.2%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)3.01%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)10
Avg Revenue beat(12)1.93%
Revenue beat(16)12
Avg Revenue beat(16)2.16%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)366.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.2%
Valuation
Industry RankSector Rank
PE 17.89
Fwd PE 19.18
P/S 2.55
P/FCF 37.39
P/OCF 25.93
P/B 2.32
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)0.35
EY5.59%
EPS(NY)0.33
Fwd EY5.21%
FCF(TTM)0.17
FCFY2.67%
OCF(TTM)0.24
OCFY3.86%
SpS2.45
BVpS2.7
TBVpS2.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.11%
ROE 2.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2.85%
GM 53.9%
FCFM 6.83%
ROA(3y)11.85%
ROA(5y)-6.42%
ROE(3y)16.19%
ROE(5y)-15.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.81%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.71%
GM growth 5Y2.65%
F-Score4
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 108.98%
Cap/Sales 3.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 239.61%
Current Ratio 6.74
Quick Ratio 5.85
Altman-Z 4.99
F-Score4
WACC14.47%
ROIC/WACCN/A
Cap/Depr(3y)157.25%
Cap/Depr(5y)107.76%
Cap/Sales(3y)2.91%
Cap/Sales(5y)2.35%
Profit Quality(3y)143.58%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-47.11%
EPS Next 2Y-22.25%
EPS Next 3Y18.46%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.17%
Revenue growth 3Y14.91%
Revenue growth 5Y5.23%
Sales Q2Q%-26.56%
Revenue Next Year-20.81%
Revenue Next 2Y-7.89%
Revenue Next 3Y13.72%
Revenue Next 5YN/A
EBIT growth 1Y-181.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.34%
OCF growth 3YN/A
OCF growth 5YN/A